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Abstract 9 
Human intestinal absorption (HIA) will dictate biopharmaceutical performance through its 10 
influence on ADME (Absorption, Distribution, Metabolism and Elimination) and can vary 11 
significantly depending upon the nature of the compound under consideration. In this study, 12 
an in vitro assay method is proposed for the prediction of HIA through the measurement of 13 
drug solubility in an aqueous phase containing micellar bile salt, namely sodium 14 
deoxycholate (NaDC). A series of twenty compounds, displaying a range of physicochemical 15 
properties and known HIA values, were analysed using UV spectroscopy to determine a 16 
solubilisation ratio (SR) for each compound. A micelle/water partition coefficient (Kxm/a) was 17 
calculated and then used to develop an equation through simple linear regression; logit HIA = 18 
-0.919 + 0.4618 logKxm/a (R
2 = 0.85). From this equation a value for % HIA was determined 19 
which compared well with literature. Furthermore, four additional drugs were then analysed 20 
using the developed equation and found to match well with literature, confirming the 21 
suitability of the method. Using a simple, economic and robust UV bile salt assay allows 22 
prediction of human intestinal absorption and avoids many of the disadvantages of other 23 
techniques, such as animal based methods.  24 
Keywords 25 
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Introduction 27 
 Human intestinal absorption (HIA) is the mechanism through which drugs traverse 28 
from the intestine into the bloodstream. The vast majority of active pharmaceutical 29 
ingredients are administered orally thus it is essential that they are absorbed within the 30 
intestine to reach the intended site of action. Although it is possible to measure the percent 31 
HIA (% HIA) during clinical studies, it is far more useful to be able to predict the value much 32 
earlier on during drug development. It is for this reason that a significant amount of research 33 
has been undertaken in an attempt to develop a reliable, robust and accurate method to predict 34 
% HIA. 35 
 Several different predictive approaches have been undertaken, including 36 
computational (in silico) methods1, such as quantitative structure-activity relationships 37 
(QSARs)2 and physiologically-based pharmacokinetic (PBPK) modelling3. These techniques 38 
have a clear advantage in that they remove the need for costly laboratory based experimental 39 
measurement yet their predictive ability can be limited. 40 
 In vitro models for the prediction of absorption include the application of dissolution 41 
analysis4, chromatographic analysis5 and dynamic gastric models6. Many of these in vitro 42 
models have included the presence of physiologically relevant solvent compositions, mainly 43 
because it is known that solvent composition dictates intestinal drug solubility which, in turn, 44 
is an important factor in determining the rate, and extent, of absorption7. The specific 45 
components within human intestinal fluids that dramatically alter drug solubility are bile 46 
salts. The main biological function of bile salts is to solubilise lipids and vitamins in the 47 
intestine with a similar effect encountered for orally administered drugs. For a full review of 48 
the absorption-enhancing effects of bile salts see Ref 88.  49 
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 In humans, the composition of bile salts is rather complex and for the purposes of this 50 
study was simplified to consider one bile salt in particular, namely sodium deoxycholate 51 
(NaDC). NaDC is a well-characterised amphiphilic molecule which can undergo micellar 52 
aggregation9, stabilised by polar interactions10, with comparatively small aggregation 53 
numbers as a result of the rigid molecular structure11. Previous research within our group has 54 
shown that NaDC, when in the presence of drugs, will exhibit modified physicochemical 55 
properties, for example a variable (drug-specific) reduction in critical micellar concentration 56 
(CMC)12. 57 
 When quantifying (or comparing) enhancement in solubility for a specific drug, or 58 
series of drugs, it is possible to evaluate the solubilisation ratio (SR), where SR is equal to the 59 
moles of drug solubilised per mole of bile salt. One study in particular calculated SR for a 60 
series of steroids and then used this data to calculate micelle/water partition coefficients 61 
(Km/w) which were then correlated with octanol/water partition coefficients (Po/w)
13. Using 62 
this same theory as a basis for drug-NaDC measurement, this paper describes the evolution of 63 
measuring SR and then using these values as the basis to form an equation to permit 64 
prediction of % HIA, thereby presenting an in vitro method to predict in vivo behaviour. 65 
 66 
Materials and Methods 67 
Materials  68 
Aqueous solutions of sodium deoxycholate (NaDC), used as purchased from Sigma 69 
Aldrich, Dorset, UK (97 %), were prepared by dilution from a 20 mM stock solution with 70 
distilled water as necessary to achieve concentrations of 7, 9, 11, 13, 17 and 20 mM (i.e. 71 
always at concentrations greater than the stable micelle CMC concentration of NaDC9b). The 72 
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24 compounds considered in this work were: acetaminophen (99 %, Sigma Aldrich, Dorset, 73 
UK), acetyl salicylic acid (99 %, Acros organics, Geel, Belgium), alprenolol (98 %, Sigma 74 
Aldrich, Dorset, UK), amitriptyline (98 %, Sigma Aldrich, Dorset, UK), carbamazepine (99 75 
%, Sigma Aldrich, Dorset, UK), cimetidine (Sigma Aldrich, Dorset, UK), diclofenac (98 %, 76 
TCI, Europe), diphenhydramine (98 %, TCI, Europe), fenoprofen (97 %, Fluka, Dorset, UK), 77 
fluconazole (98 %, Sigma Aldrich, Dorset, UK), flurbiprofen (98 %, TCI, Europe), 78 
gemfibrozil (98 %, TCI, Europe), ibuprofen (98 %, BASF, Cheshire, UK), indomethacin (99 79 
%, Sigma Aldrich, Dorset, UK), ketoprofen (98 %, Sigma Aldrich, Dorset, UK), lidocaine 80 
(98 %, Sigma Aldrich, Dorset, UK), mannitol (98 %, Sigma Aldrich, Dorset, UK), 81 
meloxicam (98 %, TCI, Europe), naproxen (98 %, Sigma Aldrich, Dorset, UK), 82 
phenylbutazone (99 %, Sigma Aldrich, Dorset, UK), piroxicam (98 %, Sigma Aldrich, 83 
Dorset, UK), propranolol (99 %, Sigma Aldrich, Dorset, UK), quinine (96 %, Fluka, Dorset, 84 
UK), terbutaline (96 % Sigma Aldrich, Dorset, UK), used as purchased. All experimental 85 
work was conducted without altering the pH or ionic strength to avoid the formation of a 86 
surfactant-gel hydropolymer. 87 
 88 
Method 89 
 A calibration plot was established at each of the 6 bile salt concentrations using the 90 
Agilent Cary 60 UV-Vis spectrophotometer set at wavelength of maximum absorbance for 91 
each drug as follows (acetaminophen ʎmax. 243 nm, acetyl salicylic acid ʎmax. 295 nm, 92 
alprenolol ʎmax. 270 nm, amitrityline ʎmax. 240 nm, carbamazepine ʎmax. 284 nm, cimetidine 93 
ʎmax. 218 nm, diclofenac ʎmax. 276 nm, diphenhydramine ʎmax. 221 nm, fenoprofen ʎmax. 271 94 
nm, fluconazole ʎmax. 260 nm, flurbiprofen ʎmax. 247 nm, gemfibrozil ʎmax. 274 nm, ibuprofen 95 
ʎmax. 272 nm, indomethacin ʎmax. 320 nm, ketoprofen ʎmax. 261 nm, lidocaine ʎmax. 262 nm, 96 
mannitol ʎmax. 295 nm, meloxicam ʎmax. 362 nm, naproxen ʎmax. 230 nm, phenylbutazone 97 
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ʎmax. 264 nm, piroxicam ʎmax. 355 nm, propranolol ʎmax. 292 nm, quinine ʎmax. 332 nm, 98 
terbutaline ʎmax. 280 nm), also the sample cell was thermostated at 37 0C. Separately, an 99 
excess of drug was added to 1 mL of each bile salt concentration in a microcentrifuge tube 100 
and placed in a shaking water bath for 48 hours at 37 ºC, then centrifuged at 13,000 rpm, 101 
filtered and diluted using the corresponding bile salt concentration. Using the regression 102 
equation obtained from the established calibration plot of each drug at each bile salt 103 
concentration, the concentration of solubilised drug was determined. A plot of the amount 104 
solubilised with bile salt concentration facilitated calculation of the solubilisation ratio (SR) 105 
whereby the mole fraction solubilised (Xm) is equal to SR/(1 + SR) and can be combined with 106 
the literature-based calculated mole fraction aqueous solubility (Xa) to determine the 107 
micelle/water partition coefficient (Kxm/a) as follows
14: 108 
Kxm/a = Xm / Xa  109 
Results from the UV analysis permitted the development of a dataset that contained 110 
logKxm/a values for 20 compounds along with their physicochemical parameters (e.g. 111 
molecular weight, rotatable bonds, molar volume, number of hydrogen bond acceptors) 112 
published human intestinal absorption (HIA) values facilitating development of an equation 113 
to relate logKxm/a with HIA using simple linear regression in combination with the established 114 
equation: 115 
Logit HIA = log [% HIA / (100 - % HIA)]  15 116 
A further four compounds were then similarly analysed by measuring logKxm/a, to predict 117 
% HIA. A comparison was then made between the predicted values with those published in 118 
literature. Simple linear regression analysis was carried out using Minitab 17® (Minitab Inc., 119 
State college, PA, USA; licensed to the University of Huddersfield) where the previously 120 
mentioned dataset was imported into it. The final model was obtained by excluding molecular 121 
descriptors which were not statistically significant (P-value > 0.05) and those with 122 
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unacceptably high levels of variance inflation factor (VIF), which is considered as a 123 
multicollinearity indicator, were not included in the final model. Cook’s distance and 124 
residuals were used to detect whether any of the model variables had high leverage. The 125 
optimal final model was then obtained including only logKxm/a as a predictor for logit HIA, 126 
the model was then validated using four compounds. 127 
 128 
Results and Discussion 129 
 In total, twenty four drugs were analysed to determine the concentration of drug in 130 
solution as a function of NaDC concentration, these were selected to cover a range of 131 
physicochemical properties, such as reported HIA, log Po/w and other properties. All data 132 
were then plotted to determine a SR value for each drug (i.e. the slope): a selection of which 133 
can be seen in Figure 1. 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
 143 
 Figure 1 clearly shows a linear relationship between the concentration of drug and the 144 
concentration of NaDC. Only linear sections of the plots were incorporated to calculate SR, 145 
some were deemed to be non-linear, such as the lower concentrations of quinine and the 146 
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higher concentrations of acetaminophen (data not shown). These non-liner relationships may 147 
be due to preferential drug-drug interactions rather than drug-NaDC interactions as such 148 
drugs are known to self-associate 16. The majority of the compounds did exhibit a linear 149 
relationship over the concentration range studied (7 – 20 mM) ensuring confidence in the 150 
experimental system. Using the calculated SR value, along with the mole fraction of aqueous 151 
solubility for the drug, facilitated calculation of a micelle/aqueous partition coefficient for 152 
each drug. By analysing these values alongside reported % HIA literature data (Table 1) 153 
enabled the application of simple linear regression to construct an equation to permit 154 
calculation of % HIA for any compound through measurement of its solubility in NaDC.  155 
 156 
 157 
 158 
 159 
 160 
 161 
 162 
 163 
 164 
Using data presented in Table 1, simple linear regression analysis was utilised to create an 165 
optimised equation to predict HIA: 166 
Logit HIA = -0.919 + 0.4618 logKxm/a 167 
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S= 0.236264 R2 = 0.8492, R2adj.= 0.8409, R
2
Pred.= 0.8232, F=101.388. The P-values obtained 168 
for this model indicate that the relationship between % HIA and logKxm/a values was 169 
statistically significant at the 95 % confidence level where they were < 0.05, also the model’s 170 
F-ratio was found to be statistically significant. logKxm/a was found to have a 95 % 171 
confidence interval of (0.365, 0.558) and a t-value of (10.069). According to Cook’s distance 172 
and residuals, no drug among the model’s dataset was found to be influential or having high 173 
leverage. The unadjusted R2 of 0.8492 derived from the current data indicates that the fit of 174 
the sampled drugs to the model is good. The R2 Pred. value of 0.8232 indicates that the fit of 175 
the drugs to the model is valid and confirms the potential suitability of UV measurement of 176 
solubility using NaDC to predict oral drug absorption in the human GI tract. The close values 177 
of R2adj and R
2
Pred. show no evidence of the current model over-fitting the data. A Durbin-178 
Watson statistic value of 2.309 proves the absence of autocorrelation in the current regression 179 
model. A summary of predicted % HIA values using the established equation alongside 180 
published literature values for % HIA can be seen in Table 2 including validation 181 
compounds.  182 
 183 
 184 
 185 
 186 
 187 
 188 
 189 
 190 
 191 
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 192 
 A plot of calculated % HIA with corresponding literature values can be seen in Figure 193 
2. 194 
 195 
 196 
 197 
 198 
 199 
 200 
 201 
 202 
Conclusions 203 
 Overall, the development of an equation to predict % HIA using a simple UV based 204 
technique via calculation of the micelle/water partition coefficient, has been shown to be 205 
statistically appropriate and reliable as a method to determine intestinal absorption. Using a 206 
simple, economic and robust UV bile salt assay allows prediction of human intestinal 207 
absorption and avoids many of the disadvantages of other techniques, such as animal based 208 
methods.  209 
 210 
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